智通财经APP讯，微创脑科学(02172)发布公告，截至2024年12月31日止年度(报告期)内，预期集团净利润约为人民币2.36亿元至人民币2.7亿元之间，较上年同期增长约75%至100%。集团2020年度至2024年度的经调整净利润实现了约55%的5年年复合增长率。
董事会认为，前述集团盈利预期大幅增长主要归功于下列原因：
(1)得益于医院覆盖及市场份额提升，且海外业务收入实现翻倍增长，报告期内集团收入预期双位数增长;
(2)通过执行供应链改善及成本节约措施，集团的运营效率提升，盈利能力显著增强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.